Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

Completed

Conditions studied: Carcinoma, Hepatocellular, Metastatic Liver Cancer

In brief

Clinical study planned to demonstrate that the BioTraceIO Lite, available post-procedure, is effective at estimating the area of tissue damage as measured on 24-hour post-procedure (T=24hrs) CECT scan and that it is safe, based on an assessment of device-related Adverse Events. Multi-center (up to 6 investigational sites) prospective single-arm clinical investigation 50 evaluable subjects total stratified by cancer type (primary hepatocellular carcinoma vs. secondary liver metastases).

Key facts

Study ID

NCT04970212

Run by

Techsomed Medical Technologies LTD

People needed

65

Starts

2021-09-24

Expected to finish

2022-10-08

Last updated by the study team

2023-04-18

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Scheduled and indicated for standard-of-care liver tissue ablation for either hepatocellular carcinoma (HCC) or metastatic liver tumor(s) using either RF or MW energy.
• At least 21 years of age
• Single tumor, or multiple tumors only if the distance between the ablated tumor and all other tumors allows for distinct separation between the necrotic zones (minimum of 1cm), based on the physician's discretion.
• Distance between the tumor and the edge of any previous necrotic zones allows for distinct separation between the necrotic zones (minimum of 1cm), based on the physician's discretion.
• Single ablation, using a single ablation needle, per tumor.
• Able and willing to give informed consent.

You may not qualify if…

• Liver tumor that cannot be ablated with a single ablation needle, according to the investigator's clinical opinion.
• Subject cannot tolerate/undergo contrast-enhanced CT.
• Planned ablation includes adjunctive means other than RF or MW energy (e.g., ethanol, hepatic artery embolization, etc.) or overlapping ablations using a single ablation needle.
• Ablation area cannot be visualized continuously using ultrasound throughout the entire ablation procedure.
• Pregnant or lactating
• Currently participating in another clinical trial of an unapproved investigational device or drug that has not concluded the follow-up period.
• Unable or unwilling to give informed consent.

Where it is running

• Mayo Clinic — Phoenix, Arizona, United States
• Stanford Medicine — Stanford, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Mayo Clinic — Rochester, Minnesota, United States
• University Hospitals Cleveland — Cleveland, Ohio, United States
• Houston Methodist Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.